Skip to main content
Top
Published in: Inflammation 3/2016

01-06-2016 | EDITORIAL

Nobiletin: A Citrus Isolate to Make Sepsis Less Sour

Authors: Patrick M. Honore, Rita Jacobs, Inne Hendrickx, Elisabeth De Waele, Herbert D. Spapen

Published in: Inflammation | Issue 3/2016

Login to get access

Excerpt

Septic shock remains a major concern in critically ill patients. Morbidity, as reflected by cardiovascular instability and sequential organ failure, is high and mortality ranges from 20 to 50 % [1]. Treatment options are scarce and mainly cause-oriented and symptomatic. Substantial efforts to control the coordinate but sometimes profuse and potentially lethal sepsis-induced immuno-inflammatory response remained unsuccessful. Indeed, large studies investigating numerous “magic bullets” interfering with sepsis-related immune-inflammatory or coagulation processes failed to show efficacy on relevant outcome parameters [24]. Also, the theoretical benefit of blood purification by restoring immune homeostasis through indiscriminate removal of inflammatory mediators could not be confirmed [5]. …
Literature
2.
go back to reference Cohen, J., J.L. Vincent, N.K. Adhikari, F.R. Machado, D.C. Angus, T. Calandra, et al. 2015. Sepsis: a roadmap for future research. Lancet Infectious Diseases 5: 581–614.CrossRef Cohen, J., J.L. Vincent, N.K. Adhikari, F.R. Machado, D.C. Angus, T. Calandra, et al. 2015. Sepsis: a roadmap for future research. Lancet Infectious Diseases 5: 581–614.CrossRef
3.
go back to reference Panacek, E.A., J.C. Marshall, T.E. Albertson, D.H. Johnson, S. Johnson, R.D. MacArthur, et al. 2004. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Critical Care Medicine 232: 2173–2182.CrossRef Panacek, E.A., J.C. Marshall, T.E. Albertson, D.H. Johnson, S. Johnson, R.D. MacArthur, et al. 2004. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Critical Care Medicine 232: 2173–2182.CrossRef
4.
go back to reference Ranieri, V.M., B.T. Thompson, P.S. Barie, J.F. Dhainaut, I.S. Douglas, S. Finfer, et al. 2012. Drotrecogin alfa (activated) in adults with septic shock. The New England Journal of Medicine 366: 2055–2064.CrossRefPubMed Ranieri, V.M., B.T. Thompson, P.S. Barie, J.F. Dhainaut, I.S. Douglas, S. Finfer, et al. 2012. Drotrecogin alfa (activated) in adults with septic shock. The New England Journal of Medicine 366: 2055–2064.CrossRefPubMed
5.
go back to reference Joannes-Boyau, O., P.M. Honoré, P. Perez, S.M. Bagshaw, H. Grand, J.L. Canivet, et al. 2013. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): A multicentre randomized controlled trial. Intensive Care Medicine 39: 1535–1546.CrossRefPubMed Joannes-Boyau, O., P.M. Honoré, P. Perez, S.M. Bagshaw, H. Grand, J.L. Canivet, et al. 2013. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): A multicentre randomized controlled trial. Intensive Care Medicine 39: 1535–1546.CrossRefPubMed
6.
go back to reference Li F, Wang X, Niu X, Zhang H, He Z, Wang Y et al. 2016. Protective effects of nobiletin against endotoxic shock in mice through inhibiting TNF-α, IL-6, HMGB1 and regulating NF-κB pathway. Inflammation Li F, Wang X, Niu X, Zhang H, He Z, Wang Y et al. 2016. Protective effects of nobiletin against endotoxic shock in mice through inhibiting TNF-α, IL-6, HMGB1 and regulating NF-κB pathway. Inflammation
7.
go back to reference Wang, H., O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, J. Che, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251.CrossRefPubMed Wang, H., O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, J. Che, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251.CrossRefPubMed
8.
go back to reference Yang, H., H. Wang, S.S. Chavan, and U. Andersson. 2015. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Molecular Medicine 21(Suppl 1): S6–S12.CrossRefPubMedPubMedCentral Yang, H., H. Wang, S.S. Chavan, and U. Andersson. 2015. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Molecular Medicine 21(Suppl 1): S6–S12.CrossRefPubMedPubMedCentral
9.
go back to reference Bianchi, M.E. 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of Leukocyte Biology 81: 1–5.CrossRefPubMed Bianchi, M.E. 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of Leukocyte Biology 81: 1–5.CrossRefPubMed
10.
go back to reference Rouhiainen, A., S. Tumova, L. Valmu, N. Kalkkinen, and H. Rauvala. 2007. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). Journal of Leukocyte Biology 81: 49–58.CrossRefPubMed Rouhiainen, A., S. Tumova, L. Valmu, N. Kalkkinen, and H. Rauvala. 2007. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). Journal of Leukocyte Biology 81: 49–58.CrossRefPubMed
11.
12.
go back to reference Qin, S., H. Wang, R. Yuan, H. Li, M. Ochani, K. Ochani, et al. 2006. Role of HMGB1 in apoptosis-mediated sepsis lethality. The Journal of Experimental Medicine 203: 1637–1642.CrossRefPubMedPubMedCentral Qin, S., H. Wang, R. Yuan, H. Li, M. Ochani, K. Ochani, et al. 2006. Role of HMGB1 in apoptosis-mediated sepsis lethality. The Journal of Experimental Medicine 203: 1637–1642.CrossRefPubMedPubMedCentral
13.
go back to reference Ueno, H., T. Matsuda, S. Hashimoto, F. Amaya, Y. Kitamura, M. Tanaka, et al. 2004. Contributions of high mobility group box protein in experimental and clinical acute lung injury. American Journal of Respiratory and Critical Care Medicine 170: 1310–1316.CrossRefPubMed Ueno, H., T. Matsuda, S. Hashimoto, F. Amaya, Y. Kitamura, M. Tanaka, et al. 2004. Contributions of high mobility group box protein in experimental and clinical acute lung injury. American Journal of Respiratory and Critical Care Medicine 170: 1310–1316.CrossRefPubMed
14.
go back to reference Yang, H., M. Ochani, J. Li, X. Qiang, M. Tanovic, H.E. Harris, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101: 296–301.CrossRefPubMedPubMedCentral Yang, H., M. Ochani, J. Li, X. Qiang, M. Tanovic, H.E. Harris, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101: 296–301.CrossRefPubMedPubMedCentral
15.
go back to reference Nosaka, N., M. Yashiro, M. Yamada, Y. Fujii, H. Tsukahara, K. Liu, et al. 2015. Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice. Critical Care 19: 249.CrossRefPubMedPubMedCentral Nosaka, N., M. Yashiro, M. Yamada, Y. Fujii, H. Tsukahara, K. Liu, et al. 2015. Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice. Critical Care 19: 249.CrossRefPubMedPubMedCentral
16.
go back to reference Yumoto, M., O. Nishida, K. Moriyama, Y. Shimomura, T. Nakamura, N. Kuriyama, et al. 2011. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Therapeutic Apheresis and Dialysis 15: 385–393.CrossRefPubMed Yumoto, M., O. Nishida, K. Moriyama, Y. Shimomura, T. Nakamura, N. Kuriyama, et al. 2011. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Therapeutic Apheresis and Dialysis 15: 385–393.CrossRefPubMed
17.
go back to reference Honore, P.M., R. Jacobs, O. Joannes-Boyau, J. De Regt, E. De Waele, V. van Gorp, et al. 2013. Newly designed CRRT membranes for sepsis and SIRS—a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO Journal 59: 99–106.CrossRefPubMed Honore, P.M., R. Jacobs, O. Joannes-Boyau, J. De Regt, E. De Waele, V. van Gorp, et al. 2013. Newly designed CRRT membranes for sepsis and SIRS—a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO Journal 59: 99–106.CrossRefPubMed
18.
go back to reference Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends in Immunology 25: 280–288.CrossRefPubMed Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends in Immunology 25: 280–288.CrossRefPubMed
19.
go back to reference Liu, S.F., and A.B. Malik. 2006. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology 290: L622–L645.CrossRefPubMed Liu, S.F., and A.B. Malik. 2006. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology 290: L622–L645.CrossRefPubMed
20.
go back to reference Conti, L., S. Lanzardo, M. Arigoni, R. Antonazzo, E. Radaelli, D. Cantarella, et al. 2013. The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB Journal 27: 4731–4744.CrossRefPubMed Conti, L., S. Lanzardo, M. Arigoni, R. Antonazzo, E. Radaelli, D. Cantarella, et al. 2013. The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB Journal 27: 4731–4744.CrossRefPubMed
Metadata
Title
Nobiletin: A Citrus Isolate to Make Sepsis Less Sour
Authors
Patrick M. Honore
Rita Jacobs
Inne Hendrickx
Elisabeth De Waele
Herbert D. Spapen
Publication date
01-06-2016
Publisher
Springer US
Published in
Inflammation / Issue 3/2016
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-016-0319-1

Other articles of this Issue 3/2016

Inflammation 3/2016 Go to the issue